CUREVAC N V's ticker is CVAC and the CUSIP is N2451R105. A total of 85 filers reported holding CUREVAC N V in Q1 2023. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $89,593 | -31.3% | 26,351 | -38.7% | 0.01% | -23.5% |
| Q1 2024 | $130,348 | +19.6% | 43,019 | +66.2% | 0.02% | -19.0% |
| Q4 2023 | $108,984 | +178.1% | 25,887 | +351.2% | 0.02% | +90.9% |
| Q3 2023 | $39,191 | +28.2% | 5,738 | +95.6% | 0.01% | +22.2% |
| Q2 2023 | $30,572 | +45.8% | 2,934 | -2.5% | 0.01% | +28.6% |
| Q1 2023 | $20,966 | +79.9% | 3,008 | +55.6% | 0.01% | +40.0% |
| Q4 2022 | $11,656 | -16.7% | 1,933 | +10.1% | 0.01% | -16.7% |
| Q3 2022 | $14,000 | – | 1,756 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 370,385 | $17,241,000 | 4.81% |
| Novo Holdings A/S | 201,642 | $9,386,000 | 0.47% |
| Vivo Capital, LLC | 169,825 | $7,905,000 | 0.46% |
| Baillie Gifford | 3,896,475 | $181,381,000 | 0.12% |
| DekaBank Deutsche Girozentrale | 435,500 | $21,707,000 | 0.10% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 69,176 | $3,220,000 | 0.08% |
| HHLR ADVISORS, LTD. | 186,183 | $8,667,000 | 0.07% |
| Pinz Capital Management, LP | 3,600 | $168,000 | 0.06% |
| Cutler Group LLC / CA | 18,400 | $856,000 | 0.05% |
| ETF MANAGERS GROUP, LLC | 35,722 | $1,632,000 | 0.05% |